Oncology

Review top news and interview highlights from the week ending December 24, 2021.

All patients achieved a complete response at 3 months.

Patients treated with liso-cel had a probability of continued response at 2-years of 49.5%.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH study of fitusiran.

Poseida’s announcement follows their presentation of positive data in metastatic castrate-resistant prostate cancer in September 2021.

The professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.

PET/CT plays a central role in evaluating response after CAR T-cell therapy.

Review top news and interview highlights from the week ending December 17, 2021.

Safety and the recommended dose of CYAD-211 and the lymphodepletion regimen served as the primary end point of the study.

Patients treated with cilta-cel had a 76% reduction in the risk of death compared to patients treated with physician's choice of treatment.

The vice chair, Blood and Marrow Transplant and Cellular Immunotherapy Program, and co-leader, Immuno-Oncology, Moffitt Cancer Center, discussed the results of the phase 3 ZUMA-7 trial.

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed safety findings from the phase 3 ALLELE study.

The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.

ADI-001 does not require genetic engineering to remove TCRs to avoid GvHD, making them ideal for an off-the-shelf cell therapy.

The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.

The hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Patients treated with the CAR T-cell therapy had an over 4-fold increase in event-free survival.

Review top news and interview highlights from the week ending December 9, 2021.

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.

Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.

The hematologists from Moffitt Cancer Center and MD Anderson discussed managing CAR T-cell therapy-associated toxicities.

The hematologists from Moffitt Cancer Center and The University of Texas MD Anderson Cancer Center discussed CAR T-associated toxicities.

Adicet Bio reported positive interim data from the phase 1 GLEAN study.

The companies will combine Imugene’s CF33-CD19 oncolytic virus and Celularity’s investigational placental-derived CAR T-cell therapy.

Further understanding of how COVID-19 vaccinations affect CAR T-cell therapy recipients is needed.